Lancet Oncol 2017 Jun
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Related Questions
Or do you wait for platinum resistance?
New answer by at Vanderbilt University School of Medicine (October 1, 2018)
Bevacizumab was approved for use in combination with chemotherapy followed by continued bevacizumab maintenance in patients with platinum-sensitive recurrent ovarian cancer in...
Patient has been treated with carbo/taxol, hormonal therapies, and trametinib to date.
New answer by at UCLA David Geffen School of Medicine/UCLA Medical Center (October 19, 2020)
A couple of things to consider for this case, #1 treatment-free interval #2 platinum-free interval #3 bulky disease? #4 recent tumor profiling #5 HRD status? I am assuming tha...